Overview

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Status:
Active, not recruiting

Trial end date:
2028-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to test if the combination of enzalutamide and metformin in patients with castration resistant prostate cancer CRPC progressing on androgen deprivation therapy ADT is more effective compared to enzalutamide alone. The half of the patients will receive the experimental treatment combination, enzalutamide and metformin, while the other half will receive enzalutamide alone.

Phase:

Phase 2

Details

Lead Sponsor:

Swiss Group for Clinical Cancer Research

Treatments:

Metformin